Y A Li1, R Tsang2, S Desai1, H Deehan1. 1. Public Health Agency of Canada, Centre for Immunization and Respiratory Infectious Diseases, Ottawa, Ontario. 2. Public Health Agency of Canada, National Microbiology Laboratory, Winnipeg, Manitoba.
Abstract
OBJECTIVE: The purpose of this report is to describe the epidemiology of invasive meningococcal disease (IMD) in Canada from 2006 to 2011. METHODS: Data from the Enhanced Invasive Meningococcal Disease Surveillance System and national population estimates were selected for descriptive and inferential analyses. The geographic, demographic, seasonal and subtype distributions as well as clinical characteristics of the IMD cases were examined. Incidence and mortality rates were calculated per 100,000 population per year; 95% confidence intervals (CI) were calculated for rate comparison. The direct method was used for age standardization. Proportions were compared using the chi-squared test at a p<0.05 significance level. RESULTS: During the study period, the mean incidence rates of IMD were 0.58 (total), 0.33 (serogroup B), 0.07 (serogroup C), 0.03 (serogroup W-135) and 0.10 (serogroup Y). The median age for serogroups B, C, W-135 and Y was 16, 43, 38 and 47 years respectively. The mean age-specific incidence rates among infants under 1 year of age (7.35, CI: 5.38-9.32) and children from 1 to 4 years of age (1.89, CI: 1.54-2.24) were significantly higher than those in any other age group. The mean case fatality ratio was 8.1% (range 4.3%-14.3%). The average number of cases that occurred per month was significantly higher (p<0.0001) in winter (18 cases) than in summer (12 cases). CONCLUSION: IMD is still endemic in Canada. Although individuals at any age can be affected, infants under 1 year of age are at the greatest risk, followed by children aged 1-4 years and individuals aged 15-19 years. Following the implementation of routine childhood immunization programs with monovalent meningococcal C conjugate vaccines (MenC) in all provinces and territories (beginning in 2007), the incidence of serogroup C has decreased significantly over the study period and is now at an all-time low. Serogroup B is the leading cause of IMD, and diseases of serogroup W-135 and Y have stabilized at relatively lower incidence rates. With the addition of immunization programs using quadrivalent conjugate meningococcal vaccines (MCV4), we would expect further reductions in the incidence of meningococcal infection in Canada.
OBJECTIVE: The purpose of this report is to describe the epidemiology of invasive meningococcal disease (IMD) in Canada from 2006 to 2011. METHODS: Data from the Enhanced Invasive Meningococcal Disease Surveillance System and national population estimates were selected for descriptive and inferential analyses. The geographic, demographic, seasonal and subtype distributions as well as clinical characteristics of the IMD cases were examined. Incidence and mortality rates were calculated per 100,000 population per year; 95% confidence intervals (CI) were calculated for rate comparison. The direct method was used for age standardization. Proportions were compared using the chi-squared test at a p<0.05 significance level. RESULTS: During the study period, the mean incidence rates of IMD were 0.58 (total), 0.33 (serogroup B), 0.07 (serogroup C), 0.03 (serogroup W-135) and 0.10 (serogroup Y). The median age for serogroups B, C, W-135 and Y was 16, 43, 38 and 47 years respectively. The mean age-specific incidence rates among infants under 1 year of age (7.35, CI: 5.38-9.32) and children from 1 to 4 years of age (1.89, CI: 1.54-2.24) were significantly higher than those in any other age group. The mean case fatality ratio was 8.1% (range 4.3%-14.3%). The average number of cases that occurred per month was significantly higher (p<0.0001) in winter (18 cases) than in summer (12 cases). CONCLUSION: IMD is still endemic in Canada. Although individuals at any age can be affected, infants under 1 year of age are at the greatest risk, followed by children aged 1-4 years and individuals aged 15-19 years. Following the implementation of routine childhood immunization programs with monovalent meningococcal C conjugate vaccines (MenC) in all provinces and territories (beginning in 2007), the incidence of serogroup C has decreased significantly over the study period and is now at an all-time low. Serogroup B is the leading cause of IMD, and diseases of serogroup W-135 and Y have stabilized at relatively lower incidence rates. With the addition of immunization programs using quadrivalent conjugate meningococcal vaccines (MCV4), we would expect further reductions in the incidence of meningococcal infection in Canada.
Authors: Frances B Jamieson; Prasad Rawte; Shelley L Deeks; Jianwei Zhou; Dennis K S Law; Saul Deng; Raymond S W Tsang Journal: J Med Microbiol Date: 2012-10-04 Impact factor: 2.472
Authors: Dennis K S Law; Manon Lorange; Louise Ringuette; Réjean Dion; Michel Giguère; Averil M Henderson; Jan Stoltz; Wendell D Zollinger; Philippe De Wals; Raymond S W Tsang Journal: J Clin Microbiol Date: 2006-08 Impact factor: 5.948
Authors: Jianwei Zhou; Brigitte Lefebvre; Saul Deng; Rodica Gilca; Genevieve Deceuninck; Dennis K S Law; Philippe De Wals; Raymond S W Tsang Journal: J Clin Microbiol Date: 2012-02-15 Impact factor: 5.948
Authors: Rsw Tsang; L Hoang; G J Tyrrell; G Horsman; P Van Caeseele; F Jamieson; B Lefebvre; D Haldane; R R Gad; G J German; G Zahariadis Journal: Can Commun Dis Rep Date: 2017-07-06
Authors: R S Tsang; L Hoang; G J Tyrrell; J Minion; P Van Caeseele; J V Kus; B Lefebvre; D Haldane; R Garceau; G German; G Zahariadis; B Hanley Journal: Can Commun Dis Rep Date: 2019-06-06
Authors: Thomas E Delea; Derek Weycker; Mark Atwood; Dion Neame; Fabián P Alvarez; Evelyn Forget; Joanne M Langley; Ayman Chit Journal: PLoS One Date: 2017-05-04 Impact factor: 3.240
Authors: Raymond S W Tsang; Dennis K S Law; Rosita De Paola; Maria Giuliani; Maria Stella; Jianwei Zhou; Saul Deng; Giuseppe Boccadifuoco; Marzia Monica Giuliani; Laura Serino Journal: mSphere Date: 2020-03-04 Impact factor: 4.389
Authors: Hirotaka Yamashiro; Nora Cutcliffe; Simon Dobson; David Fisman; Ronald Gold Journal: Can J Infect Dis Med Microbiol Date: 2015 Jul-Aug Impact factor: 2.471